Skip to main content

Table 3 Incidence of adverse reactions within 0–30 days by symptoms

From: A post-marketing study to evaluate the safety and immunogenicity of a quadrivalent influenza split-virion vaccine in elderly people aged 60 years and older

Symptoms (PT)

N

n

Incidences (95%CI)

Vaccination site pain

1399

35

2.50(1.75 ~ 3.46)

Vaccination site pruritus

1399

6

0.43(0.16 ~ 0.93)

Cough

1399

4

0.29(0.08 ~ 0.73)

Vomiting

1399

3

0.21(0.04 ~ 0.63)

Vaccination site swelling

1399

2

0.14(0.02 ~ 0.52)

Vaccination site erythema

1399

2

0.14(0.02 ~ 0.52)

Headache

1399

2

0.14(0.02 ~ 0.52)

Fatigue

1399

2

0.14(0.02 ~ 0.52)

Nausea

1399

2

0.14(0.02 ~ 0.52)

Pyrexia

1399

1

0.07(0.00 ~ 0.40)

Dizziness

1399

1

0.07(0.00 ~ 0.40)

Arthralgia

1399

1

0.07(0.00 ~ 0.40)

Myalgia

1399

1

0.07(0.00 ~ 0.40)

  1. PTs in descending order of incidence;
  2. CI: confidence intervals;
  3. N: subject number of analyzing set as denominator; n: number of subjects developed corresponding reactions